July 8, 2018

BD Acquires TVA Medical

July 9, 2018—BD (Becton, Dickinson and Company) announced the completion of its acquisition of TVA Medical, Inc., which develops minimally invasive vascular access solutions for patients with chronic kidney disease requiring hemodialysis.

With the acquisition, BD will offer TVA Medical's everlinQ endoAVF system, an endovascular arteriovenous fistula creation technology for the treatment of patients with end-stage renal disease. The product name will be transitioned to the WavelinQ EndoAVF system during the integration of the company.

On June 22, the US Food and Drug Administration announced de novo marketing authorization for the everlinQ endoAVF system. The device is already commercially available in Europe and Canada.

Terms of the transaction were not disclosed. Future financial results for TVA Medical will be reported under the Peripheral Intervention business within the Interventional Segment at BD.

Subscribe to our weekly newsletter.

Stay informed on the week's top stories including literature summaries, device approvals, guideline changes, and more. Plus, get our latest issues & supplements delivered to your inbox each month.

July 8, 2018

BD Acquires TVA Medical

Current Issue

Keep In Touch